About US
Contact us
-
In a busy month, Pfizer extends recall of blood pressure meds to the UKAdd another country to the recall list for Pfizer’s blood pressure medicines. Monday, the companypulled(PDF) one lot of Accuretic off shelves in the U.K., continuing its busy month of voluntary2022/3/30
-
Aurobindo strikes branded generics buyout to build biosimilars 'launch pad' in IndiaAurobindo Pharma is already a generics force to be reckoned with in the U.S. Now, the company has clinched a deal to tap into the burgeoning biosimilars market in its home country of India. Aur2022/3/28
-
On a roll, Sanofi raises Dupixent's peak sales target to €13B-plusOver the years, asSanofi and Regeneron's Dupixentracked up new indications and approached the French pharma giant's 10 billion euro peak sales goal, analysts had started to wonder whether the drug mi2022/3/28
-
Genentech suffers loss in Esbriet patent dispute with Sandoz, Teva and moreAfter whittling down Genentech’s defenses at a bench trial last fall, Novartis’ Sandoz unit has removed a major hurdle on the path to launching itsEsbriet copycat. A Delaware federal judge has2022/3/25
-
Merck telegraphs closure of Pennsylvania antibiotics plant that employs 300Some 300 Merck & Co. staffers’ jobs are on the cutting board after the company confirmed plans to shutter its Cherokee manufacturing plant. Merck aims to mothball production at the facility2022/3/25
-
Merck, building on Keytruda’s landmark biomarker nod, pressures GSK's limited I-O position with new FDA approvalIn a historic FDA go-ahead in 2017, Merck & Co.’s Keytruda became the first treatment for cancers with a specific genetic feature regardless of their location. Now, the immunotherapy has expanded2022/3/23
-
After price deal, Takeda's lung cancer drug Exkivity wins UK green light ahead of J&J rivalIn their running battle to treat a rare form of non-small cell lung cancer, Johnson & Johnson got the jump on Takeda in the United States last year. But now Takeda has one-upped J&J in the U.2022/3/23
-
Pfizer's deal with Medicines Patent Pool includes 35 companies from 12 countries to produce generic PaxlovidAs the coronavirus surged around the globe, Pfizer was among the vaccine makers who had to fend off criticism for protecting the technology behind its COVID-19 shots. Upon the development of its COVI2022/3/21
-
Eisai's reduced Aduhelm role; Chinese biotechs' US delisting risks; Zai Lab's new COO from LillyEisai has decided to exit its supporting role for Biogen's Alzheimer's drug Aduhelm. Chinese companies including several biotechsface potential U.S. delisting if they fail to comply with a new audit2022/3/21
-
After Alexion buyout, AstraZeneca pays Roche $775M to settle Ultomiris patent brawlAstraZeneca and Roche recently decided to end a patent infringement fight around Ultomiris. Now, we know the price of the deal. AstraZeneca’s Alexion willpay$775 million to Roche’s Chugai Pharm2022/3/18